Literature DB >> 21044858

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

James B Leverenz1, G Stennis Watson, Jane Shofer, Cyrus P Zabetian, Jing Zhang, Thomas J Montine.   

Abstract

We tested the hypothesis that levels of CSF biomarkers associated with dementia and cognitive impairment are correlated with cognitive performance in non-demented Parkinson's disease (PD) patients. Twenty-two non-demented patients with PD underwent neuropsychological testing and lumbar puncture to collect CSF. We correlated performance scores on the Logical Memory (delayed), Category Fluency, Digit Symbol, and Trails B minus A with CSF concentrations of amyloid (A) β(42), total tau (t-tau), Aβ(42)/t-tau, and Brain Derived Neurotrophic Factor (BDNF). We observed significant associations between performance on the Digit Symbol test and CSF levels of Aβ(42), Aβ(42)/t-tau, and BDNF, and between performance on the Category Fluency (vegetable) and Aβ(42)/t-tau. While several of these associations were attenuated by adjusting for age, our results suggest that it may be possible to use CSF biomarkers to characterize pathophysiologic processes underlying even mild cognitive deficits in non-demented PD patients.
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044858      PMCID: PMC3071582          DOI: 10.1016/j.parkreldis.2010.10.003

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  16 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia.

Authors:  W P Goldman; J D Baty; V D Buckles; S Sahrmann; J C Morris
Journal:  Arch Neurol       Date:  1998-05

3.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

4.  CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

Authors:  Thomas J Montine; Min Shi; Joseph F Quinn; Elaine R Peskind; Suzanne Craft; Carmen Ginghina; Kathryn A Chung; Hojoong Kim; Douglas R Galasko; Joseph Jankovic; Cyrus P Zabetian; James B Leverenz; Jing Zhang
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

5.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

7.  Clinical phenotype of Parkinson disease dementia.

Authors:  James E Galvin; Jori Pollack; John C Morris
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

8.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases.

Authors:  Jing Zhang; Izabela Sokal; Elaine R Peskind; Joseph F Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A Chung; Steven P Millard; John G Nutt; Thomas J Montine
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

9.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Authors:  G Li; I Sokal; J F Quinn; J B Leverenz; M Brodey; G D Schellenberg; J A Kaye; M A Raskind; J Zhang; E R Peskind; T J Montine
Journal:  Neurology       Date:  2007-08-14       Impact factor: 9.910

10.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03
View more
  25 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

Review 2.  Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.

Authors:  Katherine Leaver; Kathleen L Poston
Journal:  Neuropsychol Rev       Date:  2015-12-01       Impact factor: 7.444

3.  CSF biomarkers in different phenotypes of Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

Review 4.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

Review 5.  CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD.

Authors:  Claudio Liguori; Federico Paolini Paoletti; Fabio Placidi; Roberta Ruffini; Giulia Maria Sancesario; Paolo Eusebi; Nicola Biagio Mercuri; Lucilla Parnetti
Journal:  Curr Neurol Neurosci Rep       Date:  2019-01-14       Impact factor: 5.081

6.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

Review 7.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 8.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

9.  Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Authors:  Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

10.  Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Authors:  Ragnhild E Skogseth; Kolbjorn Bronnick; Joana B Pereira; Brit Mollenhauer; Daniel Weintraub; Tormod Fladby; Dag Aarsland
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.